- Home
- ALGS vs PLUR Comparison
ALGS vs PLUR Comparison
Compare ALGS & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | PLUR |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 33.9M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ALGS | PLUR |
|---|---|---|
| Price | $6.37 | $3.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.33 | $12.00 |
| AVG Volume (30 Days) | ★ 188.6K | 4.3K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,186,000.00 | $1,336,000.00 |
| Revenue This Year | $32.20 | $97.38 |
| Revenue Next Year | $4.71 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $4.20 | $2.82 |
| 52 Week High | $13.69 | $6.10 |
Technical Indicators
Market Signals| Indicator | ALGS | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 47.96 |
| Support Level | N/A | $3.12 |
| Resistance Level | $8.03 | $3.42 |
| Average True Range (ATR) | 0.72 | 0.14 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 13.33 | 21.64 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.